Speaker illustration

Professor Richard Channick

David Geffen School of Medicine at UCLA, Los Angeles (United States of America)

Richard Channick, MD, is Professor of Medicine at David Geffen School of Medicine at UCLA and Director of the Pulmonary Vascular Disease Program at UCLA Medical Center. Dr. Channick received his medical degree from Temple University Medical School, where he was elected to the Alpha Omega Alpha Medical Honor Society. Dr. Channick was at UCSD for 20 years helping build the pulmonary vascular program there. Between 2009 and 2018, he was at Massachusetts General Hospital, Harvard Medical School where he built a large Pulmonary Vascular Program. He has been at UCLA since September 2018, directing the UCLA PH program as well as the Acute and Chronic Thromboembolic Disease Program. Dr. Channick has published over 200 original articles, chapters and reviews focused on all aspects of pulmonary vascular disease . Dr. Channick has served on the steering committees for several pivotal clinical trials in pulmonary hypertension and lectures nationally and internationally.

Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: Real-world data from OPUS and OrPHeUS

Event: ESC Congress 2022

Topic: Pulmonary Hypertension

Session: Pulmonary hypertension around the real world

Thumbnail

Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): combined data from OPUS and OrPHeUS real-world data sets

Event: ESC CONGRESS 2019

Topic: Pulmonary Hypertension

Session: Chronic venous thromboembolism

Thumbnail

ESC 365 is supported by

logo Novo Nordisk